Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1839 | 2393 | 43.1 | 84% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | HIV 1 INTEGRASE | Author keyword | 265 | 83% | 6% | 150 |
2 | INTEGRASE | Author keyword | 236 | 54% | 13% | 300 |
3 | RALTEGRAVIR | Author keyword | 126 | 55% | 7% | 159 |
4 | DOLUTEGRAVIR | Author keyword | 102 | 83% | 2% | 58 |
5 | INTEGRASE INHIBITOR | Author keyword | 94 | 69% | 3% | 80 |
6 | ELVITEGRAVIR | Author keyword | 92 | 84% | 2% | 51 |
7 | LEDGF P75 | Author keyword | 80 | 84% | 2% | 43 |
8 | HIV INTEGRASE | Author keyword | 55 | 69% | 2% | 47 |
9 | INTEGRASE INHIBITORS | Author keyword | 55 | 58% | 3% | 64 |
10 | MK 0518 | Author keyword | 30 | 100% | 1% | 12 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HIV 1 INTEGRASE | 265 | 83% | 6% | 150 | Search HIV+1+INTEGRASE | Search HIV+1+INTEGRASE |
2 | INTEGRASE | 236 | 54% | 13% | 300 | Search INTEGRASE | Search INTEGRASE |
3 | RALTEGRAVIR | 126 | 55% | 7% | 159 | Search RALTEGRAVIR | Search RALTEGRAVIR |
4 | DOLUTEGRAVIR | 102 | 83% | 2% | 58 | Search DOLUTEGRAVIR | Search DOLUTEGRAVIR |
5 | INTEGRASE INHIBITOR | 94 | 69% | 3% | 80 | Search INTEGRASE+INHIBITOR | Search INTEGRASE+INHIBITOR |
6 | ELVITEGRAVIR | 92 | 84% | 2% | 51 | Search ELVITEGRAVIR | Search ELVITEGRAVIR |
7 | LEDGF P75 | 80 | 84% | 2% | 43 | Search LEDGF+P75 | Search LEDGF+P75 |
8 | HIV INTEGRASE | 55 | 69% | 2% | 47 | Search HIV+INTEGRASE | Search HIV+INTEGRASE |
9 | INTEGRASE INHIBITORS | 55 | 58% | 3% | 64 | Search INTEGRASE+INHIBITORS | Search INTEGRASE+INHIBITORS |
10 | MK 0518 | 30 | 100% | 1% | 12 | Search MK+0518 | Search MK+0518 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TYPE 1 INTEGRASE | 396 | 85% | 9% | 209 |
2 | HIV 1 INTEGRASE | 262 | 49% | 16% | 388 |
3 | CONCERTED INTEGRATION | 189 | 94% | 3% | 66 |
4 | PROTEIN INVITRO | 188 | 92% | 3% | 73 |
5 | VIRUS TYPE 1 INTEGRASE | 187 | 74% | 6% | 139 |
6 | RETROVIRAL INTEGRASE | 175 | 90% | 3% | 75 |
7 | PREINTEGRATION COMPLEXES | 172 | 66% | 7% | 158 |
8 | RALTEGRAVIR | 166 | 58% | 8% | 193 |
9 | STRAND TRANSFER | 147 | 43% | 11% | 264 |
10 | ELVITEGRAVIR | 130 | 93% | 2% | 50 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Virtual-screening targeting Human Immunodeficiency Virus type 1 integrase-lens epithelium-derived growth factor/p75 interaction for drug development | 2015 | 2 | 59 | 83% |
Host factors for retroviral integration site selection | 2015 | 2 | 78 | 81% |
Genetic Barrier to Resistance for Dolutegravir | 2015 | 2 | 44 | 77% |
Strand transfer inhibitors of HIV-1 integrase: Bringing IN new era of antiretroviral therapy | 2010 | 68 | 77 | 86% |
HIV integrase inhibitors: a new era in the treatment of HIV | 2015 | 1 | 43 | 67% |
Characterization and Structural Analysis of HIV-1 Integrase Conservation | 2009 | 73 | 89 | 70% |
Structural biology of retroviral DNA integration | 2011 | 37 | 139 | 90% |
The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy | 2013 | 24 | 62 | 82% |
Resistance to Integrase Inhibitors | 2010 | 41 | 85 | 96% |
The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication | 2008 | 102 | 95 | 74% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL VIROL GENE THER Y | 18 | 36% | 1.7% | 41 |
2 | CST MAR ROUKOS | 17 | 100% | 0.3% | 8 |
3 | LBPA | 13 | 25% | 1.9% | 46 |
4 | MOL HUMAN RETROVIROL | 9 | 55% | 0.5% | 11 |
5 | PHYSICOCHIM PHARMACOL MACROMOL BIOL | 7 | 53% | 0.4% | 10 |
6 | UMR8113 | 5 | 35% | 0.5% | 12 |
7 | PRII | 5 | 63% | 0.2% | 5 |
8 | UMR 5097 | 5 | 24% | 0.7% | 17 |
9 | BIOL PHARMACOL STRUCT | 4 | 36% | 0.4% | 10 |
10 | INFECT DIS THER Y AREA UNIT | 4 | 67% | 0.2% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000150155 | HEPATOMA DERIVED GROWTH FACTOR//HDGF//HEPATOMA DERIVED GROWTH FACTOR HDGF |
2 | 0.0000122557 | ETRAVIRINE//RILPIVIRINE//TMC125 |
3 | 0.0000084979 | TY1//SECT EUKARYOT TRANSPOSABLE ELEMENTS//TY ELEMENTS |
4 | 0.0000070024 | VPR//VPX//HIV 1 VPR |
5 | 0.0000068523 | CHEM TECHNOL DRUGS//2 MERCAPTOBENZENESULFONAMIDE//2 MERCAPTOBENZENESULFONAMIDES |
6 | 0.0000067645 | LENTIVIRAL VECTOR//LENTIVIRAL VECTORS//EXPT HEMATOL |
7 | 0.0000059001 | TRIM5 ALPHA//TRIMCYP//TRIM5 |
8 | 0.0000057359 | NNRTIS//REVERSE TRANSCRIPTASE//HIV 1 REVERSE TRANSCRIPTASE |
9 | 0.0000055718 | HIV LATENCY//HIV CURE//HIV 1 LATENCY |
10 | 0.0000051168 | ATAZANAVIR//RITONAVIR//LOPINAVIR |